Last reviewed · How we verify

NCT06362733: M-PRT-IS

Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth

Recruiting now NA Last updated 20 August 2025
What this trial tests

NA trial testing Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth in Autism Spectrum Disorder in 44 participants. Currently enrolling.

Timeline
11 July 2024
Primary endpoint
1 July 2026
1 July 2026

Quick facts

Lead sponsorStanford University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment44
Start date11 July 2024
Primary completion1 July 2026
Estimated completion1 July 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 4 to 17, any sex, with Autism Spectrum Disorder or Restricted Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this open label trial is to examine the preliminary feasibility, acceptability, and effectiveness of a 12-week behavioral intervention program (1 hour/week) to treat insistence on sameness (e.g., difficulty tolerating changes in routine) in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of a combination of parent-training and parent-mediated intervention with the child.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06362733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing